Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05512351 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma | recruiting | Phase 2 | 80 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05532969 | Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma | not yet recruiting | — | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 |
| clinicaltrials |
| NCT05536986 | Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma | not yet recruiting | — | 60 | Henan Provincial People's HospitalOTHER | 0 | Sep 27, 2022 | clinicaltrials |
| NCT05541042 | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | not yet recruiting | — | 50 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05552937 | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | recruiting | Phase 2 | 50 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05551208 | Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | recruiting | Phase 2 | 42 | Chongqing University Cancer HospitalOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05528783 | Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance | recruiting | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05548504 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC(HERAN2) | not yet recruiting | Phase 2 | 182 | Odense University HospitalOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05541367 | Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer | recruiting | — | 80 | Tongji HospitalOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05541601 | Prospective Cohort for Early Detection of Liver Cancer(Pearl) | recruiting | — | 3,000 | University of OxfordOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05539118 | Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Xijing HospitalOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05539768 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 8 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05228951 | Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | recruiting | Phase 2 | 12 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05263570 | The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World. | recruiting | — | 200 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05537129 | Laparoscopic vs Open Total Gastrectomy for Gastric Cancer | recruiting | N/A | 600 | Fudan UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05534906 | The Detection of Small Early Liver Cancer With Natural History Follow up(SELINA) | recruiting | — | 250 | University of OxfordOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT05339568 | Patient's Whole Process Follow-up Management(HOPE-1)(HOPE-1) | recruiting | — | 1,268 | Qianfoshan HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05510830 | Diagnostic Cervical Conization for Persistent Infection or Integration of HPV | not yet recruiting | N/A | 250 | Tongji HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05529615 | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer(CTAC) | recruiting | N/A | 2,684 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05531045 | 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma(TEP-PREDICT) | not yet recruiting | — | 222 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT04389086 | Induction Chemotherapy for Locally Recurrent Rectal Cancer(PelvEx II) | recruiting | Phase 3 | 364 | Catharina Ziekenhuis EindhovenOTHER | 5 | Sep 6, 2022 | clinicaltrials |
| NCT05527795 | Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma(Mel-ImmAdj) | recruiting | — | 1,000 | Hospices Civils de LyonOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05528237 | HPV Self-sampling to Improve Access to Cervical Cancer Screening for Persons With HIV and/or Underserved Individuals(ACCESS) | enrolling by invitation | N/A | 50 | University of WashingtonOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05276037 | Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates | recruiting | — | 350 | University of LiegeOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524090 | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer(PREOPANC-4) | recruiting | — | 223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | not yet recruiting | Phase 2 | 203 | Fujian Medical UniversityOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04699292 | International Prospective Registry on Local Treatment Approaches in MLS | recruiting | — | 300 | The Netherlands Cancer InstituteOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr(CAPRICE) | not yet recruiting | Phase 1 / Phase 2 | 72 | Institut Paoli-CalmettesOTHER | 0 | Aug 29, 2022 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05515068 | Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas(COSS-Registry) | not yet recruiting | — | 1,000 | Klinikum StuttgartOTHER | 0 | Aug 25, 2022 | clinicaltrials |
| NCT04486495 | Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer(MINIMAX) | recruiting | — | 549 | Maastricht University Medical CenterOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04108936 | Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses(CRS/HIPEC) | recruiting | — | 250 | University of RegensburgOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03645824 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)(HOVON134MF) | active not recruiting | Phase 2 | 61 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Aug 22, 2022 | clinicaltrials |
| NCT05030805 | Transcriptional Map of Ovarian Cancer at the Single Cell Level(Ova-seq) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04893876 | The OPERa Study: Evaluating QoL After Rectal Cancer Surgery | not yet recruiting | — | 1,200 | Jewish General HospitalOTHER | 0 | Aug 18, 2022 | clinicaltrials |
| NCT05505812 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | not yet recruiting | Early Phase 1 | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2022source: clinicaltrials